Skip to main content

Table 8 Composite endpoints

From: Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study

 

Arm A

Arm B

Arm C

 

n

n

n

DVT proximal

0

0

0

DVT distal

0

0

2

PE

0

0

0

Death on study

0

0

0

Exact Odds Ratios

Unadjusted

Estimate

95 % Confidence Limits

p-value

Odds Ratio

(median unbiased)

  

Arm A vs. Arm C

0.397

0 – 3.344

0.480

Arm B vs. Arm C

0.387

0 - 3.259

0.476

Noninferiority Analysis of Risk Difference

Risk Difference

Estimate

95 % Confidence Limits

p-value*

Arm C vs. Arm A

−0.0180

−0.0428 – 0.0067

<0.0001

Arm C vs. Arm B

−0.0180

−0.0428 – 0.0067

<0.0001

  1. *Using a noninferiority limit of -0.015